Cyclic peptide interleukin 5 antagonists mimic CD turn recognition epitope for receptor alpha

Area of Science:

• Biochemistry
• Immunology
• Drug Discovery

Background:

• Interleukin 5 (IL-5) is a cytokine crucial for eosinophil development and function.
• Inhibiting IL-5 signaling is a therapeutic strategy for allergic inflammatory diseases.
• Cyclic peptide AF17121, derived from library screening, inhibits IL-5 function and IL-5 receptor alpha-chain (IL-5Ralpha) binding.

Purpose of the Study:

• To elucidate the structural basis of AF17121's antagonist activity.
• To identify key residues responsible for IL-5Ralpha binding and inhibition.
• To explore the potential of AF17121 and its analogs as therapeutic agents.

Main Methods:

• Solid-phase peptide synthesis of AF17121 and its analogs with sequence variations.
• Optical biosensor interaction kinetics assays to measure binding affinities.
• Cell proliferation assays to evaluate antagonist potency against IL-5.
• Circular Dichroism (CD) spectroscopy to assess peptide secondary structure.

Main Results:

• Arginine at position 6 (Arg6) is essential for AF17121's IL-5Ralpha binding and antagonist activity.
• Acidic residues (Asp2, Glu3, Glu17, Glu18) are not critical for binding but may stabilize the peptide structure.
• Peptide analogs with Arg6 replaced by alanine showed significantly reduced competition activity.
• AF17121 exhibits a disordered structure with some beta-sheet content, unaffected by Arg6 substitution.

Conclusions:

• The arginine residue at position 6 is the primary determinant of AF17121's antagonist activity against IL-5.
• AF17121 likely mimics the IL-5 receptor alpha recognition epitope, specifically the CD turn region.
• These findings support the development of small molecule antagonists targeting IL-5 signaling.